• leader board size
Consumer Research2020-11-05T23:41:25-08:00

Consumer Research

Tilray Brands Reports Fiscal Q1 2026 Earnings

NEW YORK – Tilray Brands Inc. swung to a profit in its fiscal first quarter, fueled by record revenue and sharper cost management, as the Cannabis company builds on a multiyear turnaround. For the period ...

Week’s In Review: California Permits Lounges; Los Angeles County Targets Unlicensed Cannabis Dispensaries with “Deplatforming” Motion; California Bans Hemp-Derived THC Products Amid Regulatory Concerns; California’s New Hemp Regulations Raise Concerns for Industry and Consumers

LOS ANGELES–Welcome to the far too-exciting world of cannabis and psychedelics, where it’s a tale of two markets with some states doing amazingly well. And some, well...they're not doing so well (hello New York). Let's ...

Week’s In Review: TerrAscend Corp. Announces $10 Million Share Buyback Program; Bipartisan Lawmakers Push for MDMA Therapy for PTSD as FDA Decision Looms; Verano Acquires Cannabist Company’s Operations in Arizona and Virginia for $105 Million

LOS ANGELES–Welcome to the far too-exciting world of cannabis and psychedelics, where it’s a tale of two markets with some states doing amazingly well. And some, well...they're not doing so well (hello New York). Let's ...

Ascend Wellness Expands Recreational Cannabis Sales in Ohio

LOS ANGELES- Ascend Wellness Holdings, Inc.  a cannabis operator, announced the expansion of recreational cannabis sales in Ohio to its fifth dispensary in Carroll. The move comes after the company successfully transitioned four other locations—Cincinnati, ...

Rubicon Organics Reports Q2 2024 Financial Results

LOS ANGELES- Rubicon Organics Inc. a licensed producer specializing in organic and premium cannabis, released its financial results for the second quarter ending June 30, 2024. The company reported record net revenue of CAD 12.1 ...

Filament Health Reports Q2 2024 Results

LOS ANGELES- Filament Health Corp, a clinical psychedelic drug development company, has released its financial results for the second quarter ending June 30, 2024. The company highlighted its progress in advancing drug candidates targeting substance ...

Subscribe To Our Newsletter

Go to Top